CGEM Earnings & Financial Statements
Cullinan Therapeutics, Inc.
$13.64
-$0.46(-3.26%)
33
Overall
60
Value
18
Tech
21
Quality
Market Cap
$877.80M
Volume
903.10K
52W Range
$6.73 - $23.19
Target Price
$35.64
CGEM earnings and financial statements: Cullinan Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CGEM Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | $500.0K | $100.0K | $18.94M |
| Operating income | -$241.65M | -$196.92M | -$191.09M | $144.65M | -$67.95M |
| EBITDA | -$219.57M | -$167.15M | -$179.07M | -$132.04M | -$64.33M |
| Net income | -$219.88M | -$167.38M | -$153.16M | $111.21M | -$65.57M |
| EPS (diluted) | - | - | $-3.69 | $2.38 | $-1.52 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $448.37M | $621.82M | $484.18M | $561.12M | $437.19M |
| Total liabilities | $39.64M | $31.50M | $30.29M | $26.09M | $11.81M |
| Shareholders’ equity | $408.73M | $590.33M | $453.70M | $535.03M | $424.97M |
| Cash and equivalents | $88.33M | $83.00M | $98.43M | $156.15M | $59.77M |
| Long-term debt | $1.90M | $849.0K | $2.15M | $3.59M | $871.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$175.75M | -$145.30M | -$134.28M | -$126.66M | -$43.43M |
| Capital expenditure | -$49.0K | - | -$208.0K | -$1.13M | - |
| Free cash flow | -$175.80M | -$145.30M | -$134.48M | -$127.80M | -$43.43M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CGEM | $13.64 | -3.3% | 903.10K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cullinan Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW